(S)-tert-butyl 3-(2-bromoacetamido)pyrrolidin-1-carboxylate | 1055268-63-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-tert-butyl 3-(2-bromoacetamido)pyrrolidin-1-carboxylate
• 英文别名: (S)-3-(2-bromoacetyl)amino-1-(tert-butoxycarbonyl)pyrrolidine；tert-butyl (3S)-3-[(2-bromoacetyl)amino]pyrrolidine-1-carboxylate
• CAS: 1055268-63-7
• 化学式: C₁₁H₁₉BrN₂O₃
• 分子量: 307.187
• InChiKey: GJMPJAGFURIKQG-QMMMGPOBSA-N

物化性质

• 沸点：
  421.9±45.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl 3-(2-bromoacetamido)pyrrolidin-1-carboxylate 在 ammonium hydroxide 、 sodium iodide 作用下， 以 甲醇 、 水 为溶剂， 反应 48.0h， 以96.8%的产率得到tert-butyl (3S)-3-(2-aminoacetylamino)-1-pyrrolidinecarboxylate
  参考文献：
  名称：

  [EN] CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY
  [FR] AGENTS ANTIBACTÉRIENS DE CARBAPÉNEM AVEC ACTIVITÉ ANTI-GRAM NÉGATIF

  摘要：

  公开号：

  WO2011160020A3
• 作为产物：
  描述：

  (R)-1-(叔丁氧基羰基)-3-吡咯烷-甲磺酸酯 在 sodium azide 、 水 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 49.0h， 生成 (S)-tert-butyl 3-(2-bromoacetamido)pyrrolidin-1-carboxylate
  参考文献：
  名称：

  [EN] CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY
  [FR] AGENTS ANTIBACTÉRIENS DE CARBAPÉNEM AVEC ACTIVITÉ ANTI-GRAM NÉGATIF

  摘要：

  公开号：

  WO2011160020A3

文献信息

• Sulfonamide compound
  申请人：Matsubara Koki

  公开号：US20090048223A1

  公开（公告）日：2009-02-19

  A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G 1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G 2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; G 3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkoxycarbonyl group, an acyl group, an acyloxy group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; Y represents a single bond, or —C(R 3 )(R 4 )— (R 3 and R 4 represent hydrogen atom, or an alkyl group, or alkylene groups which combine together to form a saturated hydrocarbon ring group); G 4 represents hydroxyl group (Y is a single group), or —N(R 1 )(R 2 ) (R 1 and R 2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, a saturated heterocyclic group, an alkylsulfonyl group, an acyl group, or an amidino group); G 5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.

  由以下化学式表示的化合物：[A代表含氮饱和环；m表示0到2的整数；n表示1到4的整数；G1代表氢原子、氯原子、羟基、烷氧基或氨基；G2代表卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基；G3代表氢原子、卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基；Y代表单键，或-C(R3)(R4)-（R3和R4代表氢原子、烷基或烷烯基，它们结合在一起形成饱和碳氢环基）；G4代表羟基（Y是单个基），或-N(R1)(R2)（R1和R2代表氢原子、烷基、芳基、烯基、炔基、饱和杂环基、烷基磺酰基、酰基或胺基）；G5是A的环构成碳原子上的取代基，代表氢原子、氟原子或烷基]或其盐、或作为前药的衍生物，其强力抑制Rho激酶。
• SULFONAMIDE DERIVATIVE
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP2130828A1

  公开（公告）日：2009-12-09

  A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; G3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkoxycarbonyl group, an acyl group, an acyloxy group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; Y represents a single bond, or -C(R3)(R4)- (R3 and R4 represent hydrogen atom, or an alkyl group, or alkylene groups which combine together to form a saturated hydrocarbon ring group); G4 represents hydroxyl group (Y is a single group), or - N(R1)(R2) (R1 and R2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, a saturated heterocyclic group, an alkylsulfonyl group, an acyl group, or an amidino group); G5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.

  由式(1)代表的化合物[A 代表含氮饱和环；m 代表 0 至 2 的整数；n 代表 1 至 4 的整数；G1 代表氢原子、氯原子、羟基、烷氧基或氨基；G2 代表卤素原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷基亚磺酰基、烷基磺酰基或芳基；G3 代表氢原子、卤素原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧基羰基、酰基、酰氧基、烷基亚磺酰基、烷基磺酰基或芳基；Y 代表单键，或-C(R3)(R4)-（R3 和 R4 代表氢原子，或烷基，或结合在一起形成饱和烃环基的亚烷基）； G4 代表羟基（Y 为单个基团），或-N(R1)(R2)（R1 和 R2 代表氢原子，或烷基，或芳烷基，或烯基，或炔基，或饱和杂环基，或烷基磺酰基，或酰基，或脒基）；G5 是 A 的成环碳原子上的取代基，代表氢原子、氟原子或烷基]或其盐或其衍生物，它们是原药，能有效抑制 Rho 激酶。
• Mepyramine–JNJ7777120-hybrid compounds show high affinity to hH1R, but low affinity to hH4R
  作者：Eva Wagner、Hans-Joachim Wittmann、Sigurd Elz、Andrea Strasser

  DOI：10.1016/j.bmcl.2011.09.001

  日期：2011.11

  In literature, a synergism between histamine H-1 and H-4 receptor is discussed. Furthermore, it was shown, that the combined application of mepyramine, a H-1 antagonist and JNJ7777120, a H-4 receptor ligand leads to a synergistic effect in the acute murine asthma model. Thus, the aim of this study was to develop new hybrid ligands, containing one H-1 and one H-4 pharmacophor, connected by an appropriate spacer, in order to address both, H1R and H4R. Within this study, we synthesized nine hybrid compounds, which were pharmacologically characterized at hH(1)R and hH(4)R. The new compounds revealed (high) affinity to hH(1)R, but showed only low affinity to hH(4)R. Additionally, we performed molecular dynamic studies for some selected compounds at hH(1)R, in order to obtain information about the binding mode of these compounds on molecular level. (C) 2011 Elsevier Ltd. All rights reserved.
• CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY
  申请人：FOB Synthesis, Inc.

  公开号：EP2590978B1

  公开（公告）日：2017-09-20
• Carbapenem Antibacterials with Gram-Negative Activity
  申请人：FOB Synthesis, Inc.

  公开号：US20130172313A1

  公开（公告）日：2013-07-04

  The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.